Abstract
Only limited real-life data are available on the effects of neutralizing monoclonal antibodies in high-risk patients who have early COVID-19 and do not require supplemental oxygen. We prospectively studied 217 patients infected by the delta variant who received casirivimab plus indevimab in a dedicated ambulatory unit created during our 4th COVID wave. Mean age was 64 years, 94% had at least one comorbidity, and mean duration of symptoms was 2.9 days. Oxygen requirement, hospitalization, and mortality rates were 10, 6, and 2.8%, respectively. These results suggest benefits of early administration of neutralizing antibodies in high-risk patients infected with the delta variant.
Keywords: Ambulatory care; COVID-19; Delta variant; Monoclonal antibodies; Real life.
【저자키워드】 COVID-19, delta variant, monoclonal antibodies, Ambulatory care, Real life., 【초록키워드】 neutralizing antibody, Hospitalization, Neutralizing antibodies, variant, Delta, Comorbidity, oxygen, delta variant, monoclonal antibodies, COVID, Casirivimab, Patient, age, mortality rate, mortality rates, ambulatory, neutralizing monoclonal antibodies, neutralizing monoclonal antibody, Ambulatory care, High-risk patients, life, supplemental oxygen, early administration, Oxygen requirement, Effect, high-risk patient, benefit, duration of symptom, prospectively studied, 【제목키워드】 variant, Patient, Effectiveness,